Start-Up Quarterly Statistics: Anthos, Gossamer Lead Q1 Financings; Codiak/Jazz Deal Tops Alliances
Executive Summary
In a review of biopharma start-up dealmaking and financing activity from January through March, based on data from Strategic Transactions, Anthos completed the largest venture capital round in the first quarter, raising $250m.
You may also be interested in...
Finance Watch: Gene Therapy, Targeted Oncology Driving IPOs Despite Biopharma Stock Shakiness
Public Company Edition: Jefferies report notes robust IPO market, but SVB Leerink predicts a financing slowdown. Also, Mirati raises cash for KRAS programs after Amgen's ASCO data and a strategic shift results in job cuts at ImmunoGen.
Poseida's CAR-T, Gene Therapy Programs Get $142m Boost, Including Novartis Cash
Despite its sidetracked IPO, a registrational trial for the company's BCMA-targeting CAR-T is underway to support a late 2020 BLA filing and this new VC funding could accelerate additional programs. CAR-T pioneer Novartis is strictly an investor in the Series C round, but takes a board seat.
Hijacking The Messenger
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.